Erosion risks

• Patent challenges and settlements accelerating generic/biosimilar entry
• Product-specific patent cliffs (finite duration)
• Adverse litigation outcomes narrowing claims

Leading indicators

• Key patent litigation decisions and settlement terms (timing of generic entry)
• Biosimilar/ANDA pipeline filings and approvals
• Patent expiry timeline changes by jurisdiction

Counterarguments

• Strong IP does not prevent share loss to differentiated competitors (e.g., new GLP-1/GIP classes)
• Payer formularies can shift share even before patent expiry via rebates and preferred placement

Erosion risks

• Regulatory pathway changes (faster approvals for competitors)
• Reimbursement cuts or tighter coverage criteria
• Safety signals leading to label restrictions

Leading indicators

• Coverage policy changes by major payers
• Regulatory safety communications and label updates
• Guideline changes affecting preferred therapies

Counterarguments

• Regulatory barriers apply broadly across pharma; not uniquely advantaging one incumbent
• Large competitors have similar capabilities in regulatory execution

Erosion risks

• Competitors add large-scale capacity (internal or via CMOs)
• Manufacturing quality issues or regulatory shutdowns
• Technology shifts (new modalities) reducing relevance of existing capacity

Leading indicators

• Drug shortage notifications and backorder duration
• Capex announcements and commissioning milestones
• Fill-finish throughput and product allocation updates

Counterarguments

• Capacity advantages can be competed away with time and capital
• Supply constraints can also cap growth and reduce near-term revenue realization

Erosion risks

• Patent challenges and negotiated early-entry settlements
• Emergence of new drug classes with superior efficacy/safety
• Regulatory reforms weakening exclusivity

Leading indicators

• Semaglutide-related IP litigation updates
• Competing oral or next-gen obesity drug approvals
• Formulary positioning changes vs competitors

Counterarguments

• Even with IP, share can shift to better clinical profiles (efficacy/tolerability) from rivals
• Government/payer pressure can reduce net price independent of exclusivity

Erosion risks

• Competitor capacity catch-up (internal/CMO)
• Manufacturing reliability and quality risks
• Shift to modalities with different manufacturing constraints

Leading indicators

• Supply constraint disclosures and shipment allocation changes
• Capex pace and new site ramp milestones
• Competitor supply expansion announcements

Counterarguments

• Capacity is not a permanent moat; scale can be purchased over time
• Supply shortages can create customer dissatisfaction and reputational risk

Erosion risks

• Rapid innovation cycles (new oral entrants, new mechanisms)
• Safety/tolerability events impacting perception
• Aggressive competitor contracting and access wins

Leading indicators

• Global branded obesity market share trend vs Lilly
• Persistence/adherence and discontinuation rates
• Net price evolution (rebates, negotiated prices)

Counterarguments

• Share leadership can be driven by supply/availability, not necessarily brand trust
• Competitors with better outcomes or easier administration can flip prescriber preference quickly

Erosion risks

• New entrants with differentiated factor therapies or gene therapies
• Reimbursement tightening for high-cost specialty products
• Clinical guideline shifts toward alternative modalities

Leading indicators

• Gene therapy adoption rates and durability data in haemophilia
• Competitive trial readouts in rare endocrine and blood disorders
• Payer policy updates for specialty drugs

Counterarguments

• Regulatory barriers are industry-wide; multiple capable incumbents exist
• Innovation cycles in rare disease (including gene therapy) can bypass incumbent advantages

Erosion risks

• CMOs improving capabilities in biologics manufacturing
• Process innovations reducing learning-curve advantages
• Manufacturing deviations impacting supply and trust

Leading indicators

• Plant inspection outcomes and supply reliability
• Yield and batch success rates (if disclosed)
• Competitor manufacturing scale-ups in rare disease biologics

Counterarguments

• Contract manufacturing can reduce the uniqueness of manufacturing know-how
• Some rare disease categories are shifting toward modalities with different manufacturing requirements